Diagnostic and therapeutic management of Churg–Strauss syndrome

References

• Sablé-Fourtassou R, Cohen P, Mahr A et al. Antineutrophil cytoplasmatic antibodies and the Churg–Strauss syndrome. Abb. Intern. Med.143, 632–638 (2005).
   PubMed Web of Science ®Google Scholar
• Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteriitis nodosa. Am. J. Pathol.27, 272–301 (1951).
   Google Scholar
• Lanham J, Elkon K, Pusey C et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg–Strauss syndrome. Medicine63, 65–81 (1984).
   PubMed Web of Science ®Google Scholar
• Masi AT, Hunder GG, Lie JT et al. The American College of Rheumatology 1990 criteria for the classification of Churg–Strauss syndrome. Arthritis Rheum.33, 1094–1100 (1990).
   PubMed Web of Science ®Google Scholar
• Jennette J, Andrassy K, Bacon PA et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum.37, 187–192 (1994).
   PubMed Web of Science ®Google Scholar
• Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R et al. No difference in the incidence of vasculitides between north and south Germany: first results of the German vasculitis register. Rheumatology41, 540–549 (2002).
   PubMed Web of Science ®Google Scholar
• Harrold LR, Andrade SE, Go AS et al. Incidence of Churg–Strauss syndrome in asthma-drug users: a population based perspective. J. Rheumatol.32, 1976–1080 (2005).
   Google Scholar
• Sinico RA, Di Toma L, Maggiore U et al. Prevalence and significance of antineutrophil cytoplasmatic antibodies in Churg–Strauss syndrome. Arthritis Rheum.52, 29926–22935 (2005).
   Google Scholar
• Bottero P, Bonini M, Vecchio M et al. The common allergens in Churg–Strauss syndrome. Allergy62, 1288–1294 (2007).
   PubMed Web of Science ®Google Scholar
• Churg A, Brallas M, Cronin S et al. Formes frustes of Churg–Strauss syndrome. Chest108, 302–323 (1995).
   PubMed Web of Science ®Google Scholar
• Chumbley LC, Harrison EG Jr, DeRemee RA. Allergic granulomatosis and angiitis (Churg–Strauss syndrome). Report and analysis of 30 cases. Mayo Clin. Proc.52, 477–484 (1977).
   PubMed Web of Science ®Google Scholar
• Guillevin L, Cohen P, Gayraud M et al. Churg–Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine78, 26–37 (1999).
   PubMed Web of Science ®Google Scholar
• Solans R, Bosch JA, Perez-Bocanegra C et al. Churg–Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology40, 763–771 (2001).
   PubMed Web of Science ®Google Scholar
• Keogh KA, Specks U. Churg–Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies and leukotriene receptor antagonists. Am. J. Med.115, 284–290 (2003).
   PubMed Web of Science ®Google Scholar
• Cohen P, Pagnoux C, Mahr A et al. Churg–Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum.57(4), 686–693 (2007).
   PubMed Web of Science ®Google Scholar
• Hellemans D, Dens J, Knockaert D. Coronary involvement in the Churg–Strauss syndrome. Heart77, 576–578 (1997).
   PubMed Web of Science ®Google Scholar
• Gottlib J, Cools J, Malone JM et al. The FIP1L1–PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood103, 2879–2891 (2004).
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Seror R, Pagnoux C et al. High frequency of venous thromboembolic events in Churg–Strauss syndrome, Wegener’s granulomatosis and microscopic Polyangiitis but not Polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann. Rheum. Dis.68(4), 564–567 (2008).
   PubMed Web of Science ®Google Scholar
• Pankhurst T, Savage CO, Gordon C et al. Malignancy is increased in ANCA-associated vasculitis. Rheumatology43, 1532–1535 (2004).
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Finn D, Gunawardena D et al. Churg–Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest117, 708–713 (2000).
   PubMed Web of Science ®Google Scholar
• Cooper SM, Libman BS, Lazarovich M. Churg–Strauss syndrome in a group of patients receiving fluticasone for asthma. J. Rheumatol.29, 2651–2652 (2002).
   PubMed Web of Science ®Google Scholar
• Nepal M, Padma H. Fluticasone-associated cutaneous allergic granulomatous vasculitis: an underrecognized but important cause of drug-induced cutaneous Churg–Strauss syndrome. South Med. J.101, 761–763 (2008).
   PubMed Web of Science ®Google Scholar
• Ruppert AM, Averous G, Stanciu D et al. Development of Churg–Strauss syndrome with controlled asthma during omalizumab treatment. J. Allergy Clin. Immunol.121, 253–254 (2008).
   PubMed Web of Science ®Google Scholar
• Klion AD, Bochner BS, Gleich GJ et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J. Allergy Clin. Immunol.117, 1292–1302 (2006).
   PubMed Web of Science ®Google Scholar
• Hauser T, Mahr A, Metzler C et al. The leucotriene receptor antagonist montelukast and the risk of Churg–Strauss syndrome: a case–crossover study. Thorax63, 677–682 (2008).
   PubMed Web of Science ®Google Scholar
• Dietz A, Hubner C, Andrassy K. Macrolide antibiotic-induced vasculitis (Churg–Strauss syndrome). Laryngorhinologie77, 111–114 (1998).
   PubMed Web of Science ®Google Scholar
• Imai H, Nakamoto Y, Hirokawa M et al. Carbamazepine- induced granulomatous necrotizing angiitis with acute renal failure. Nephron.51, 405–408 (1989).
   PubMed Web of Science ®Google Scholar
• Vaglio A, Martorana D, Maggiore U et al.HLA DRB4 as a genetic risk factor for Churg–Strauss syndrome. Arthritis Rheum.56, 3159–3166 (2007).
   PubMed Web of Science ®Google Scholar
• Wieczorek S, Hellmich B, Arning L et al. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg–Strauss syndrome, but not with Wegener’s granulomatosis. Arthritis Rheum.58, 1839–1848 (2008).
   PubMedGoogle Scholar
• Tsukadiara A, Okubo Y, Kitano K et al. Eosinophil active cytokines and surface analysis of eosinophils in Churg–Strauss syndrome. Allergy Asthma Proc.20, 39–44 (1999).
   PubMed Web of Science ®Google Scholar
• Müschen M, Warskulat U, Perniok A et al. Involvement of soluble CD95 in Churg–Strauss syndrome. Am. J. Pathol.155, 915–925 (1999).
   PubMed Web of Science ®Google Scholar
• Mitsuyama H, Matsuyama W, Watanabe M et al. Increased expression of TRAIL receptor 3 in Churg–Strauss syndrome. Arthritis Rheum.56, 662–673 (2007).
   PubMedGoogle Scholar
• Schnabel A, Csernok E, Braun J et al. Inflammatory cells and cellular activation in the lower respiratory tract in Churg–Strauss syndrome. Thorax54, 771–778 (1999).
   PubMed Web of Science ®Google Scholar
• Guilpain P, Auclair JF, Tamby MC et al. Serum eosinophil protein: a marker of disease activity in Churg–Strauss syndrome. Ann. NY Acad. Sci.1107, 392–399 (2007).
   PubMed Web of Science ®Google Scholar
• Mitsuyama H, Matsuyama W, Iwakawa J et al. Increased serum vascular endothelial growth factor in Churg–Strauss syndrome. Chest129, 401–411 (2006).
   Google Scholar
• Polzer K, Karonitsch T, Neumann T et al. Eotaxin-3 is involved in Churg–Strauss syndrome – a serum marker closely correlating with disease activity. Rheumatology47, 804–808 (2008).
   PubMed Web of Science ®Google Scholar
• Schmitt W, Csernok E, Kobayashi K et al. Churg–Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum.52, 445–552 (1998).
   Google Scholar
• Kiene M, Csernok E, Müller A et al. Elevated interleukin-4 and interleukin-13 production by T-cell lines from patients with Churg–Strauss syndrome. Arthritis Rheum.44, 469–473 (2001).
   PubMed Web of Science ®Google Scholar
• Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg–Strauss syndrome. Ann. NY Acad. Sci.1051, 121–131 (2005).
   PubMed Web of Science ®Google Scholar
• Tsurikisawa N, Saito H, Tsuburai T et al. Differences in regulatory T cells between Churg–Strauss syndrome and chronic eosinophilic pneumonia with asthma. J. Allergy Clin. Immunol.122, 610–616 (2008).
   PubMed Web of Science ®Google Scholar
• Saito H, Tsurikisawa N, Tsuburai T et al. Involvement of regulatory T cells in the pathogenesis of Churg–Strauss syndrome. Int. Arch. Allergy Immunol.146(Suppl. 1), 73–76 (2008).
   PubMed Web of Science ®Google Scholar
• Falk RJ, Terrell RS, Charles LA et al. Anti-neutrophil cytoplasmatic autoantibodies induce neutrophils to degranulat and produce oxygen radicals in vitro. Proc. Natl Acad. Sci. USA87, 4115–4119 (1990).
   PubMed Web of Science ®Google Scholar
• Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest.110, 955–963 (2002).
   PubMed Web of Science ®Google Scholar
• Potter M, Fincher R, Finger D. Eosinophilia in Wegener’s granulomatosis. Chest116, 1480–1483 (1999).
   PubMed Web of Science ®Google Scholar
• Reinhold-Keller E, Beuge N, Latza U et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum.43, 1021–1032 (2000).
   PubMed Web of Science ®Google Scholar
• Chusid MJ, Dale DC, West BC et al. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine54, 1–27 (1975).
   PubMed Web of Science ®Google Scholar
• Gleich GJ, Leiferman KM, Pardani A et al. Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet359, 1577–1578 (2002).
   PubMed Web of Science ®Google Scholar
• Metzgeroth G, Walz C, Erben P et al. Safety and efficiacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a Phase-II-study. Br. J. Haematol.143, 707–715 (2008).
   PubMed Web of Science ®Google Scholar
• Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J. Rare Dis.2, 37 (2007).
   PubMed Web of Science ®Google Scholar
• Mukhytar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of primary small and medium size vessel vasculitis. Ann. Rheum. Dis.68, 310–317 (2009).
   PubMed Web of Science ®Google Scholar
• Gayraud M, Guillevin L, le Toumelin P et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis and Churg–Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum.44(3), 666–675 (2001).
   PubMed Web of Science ®Google Scholar
• Gayraud M, Guillevin L, Cohen P et al. Treatment of good-prognosis polyarteritis nodosa and Churg–Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br. J. Rheumatol.36(12), 1290–1297 (1997).
   PubMedGoogle Scholar
• Guillevin L, Fain O, Lhote F et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg–Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum.35, 208–215 (1992).
   PubMed Web of Science ®Google Scholar
• Guillevin L, Lhote F, Cohen P et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg–Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum.38, 1638–1645 (1995).
   PubMed Web of Science ®Google Scholar
• Danieli MG, Cappelli M, Malcangi G et al. Long term effectiveness of intravenous immunoglobulin in Churg–Strauss syndrome. Ann. Rheum. Dis.63, 1649–1654 (2004).
   PubMed Web of Science ®Google Scholar
• Ribi C, Cohen P, Pagnoux C et al. Treatment of Churg–Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized open-label study of seventy-two patients. Arthritis Rheum.58(2), 586–594 (2008).
   PubMed Web of Science ®Google Scholar
• Metzler C, Hellmich B, Gause A et al. Churg Strauss syndrome – successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin. Exp. Rheumatol.22(6 Suppl. 36), S52–S61 (2004).
   PubMed Web of Science ®Google Scholar
• Tatsis E, Schnabel A, Gross WL. Interferon-α treatment of four patients with Churg–Strauss syndrome. Ann. Intern. Med.129(5), 370–374 (1998).
   PubMed Web of Science ®Google Scholar
• Metzler C, Lamprecht P, Hellmich B et al. Leucencephalopathy after treatment of Churg–Strauss syndrome with interferon α. Ann. Rheum. Dis.64(8), 1242–1243 (2005).
   PubMed Web of Science ®Google Scholar
• Metzler C, Schnabel A, Gross WL et al. A Phase II study of interferon-α for the treatment of refractory Churg–Strauss syndrome. Clin. Exp. Rheumatol.26(3 Suppl. 49), S35–S40 (2008).
   PubMed Web of Science ®Google Scholar
• Arbach O, Gross WL, Gause A. Treatment of refractory Churg–Strauss-syndrome (CSS) by TNF-α blockade. Immunobiology206(5), 496–501 (2002).
   PubMed Web of Science ®Google Scholar
• Koukoulaki M, Smith KG, Jayne DR. Rituximab in Churg–Strauss syndrome. Ann. Rheum. Dis.65(4), 557–559 (2006).
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Klion AD, Roufosse FE et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N. Engl. J. Med.358(12), 1215–1228 (2008).
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med.360, 985–993 (2009).
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med.360, 973–984 (2009).
   PubMed Web of Science ®Google Scholar
• Hellmich B, Kausch I, Doehn C et al. Urinary bladder cancer in Wegener’s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum.43(8), 1841–1848 (2000).
   PubMedGoogle Scholar
• Talar-Williams C, Hijazi YM, Walther MM et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener’s granulomatosis. Ann. Intern. Med.124, 477–484 (1996).
   PubMed Web of Science ®Google Scholar
• Knight A, Askling J, Granath F et al. Urinary bladder cancer in Wegener’s granulomatosis: risks and relation to cyclophosphamide. Ann. Rheum. Dis.63, 1307–1311 (2004).
   PubMed Web of Science ®Google Scholar
• Charlier C, Henegar C, Launay O et al. Risk factors for major infections in Wegner’s granulomatosis: analysis of 113 patients. Ann. Rheum. Dis.86, 658–663 (2009).
   Google Scholar
• Ognibene FP, Shelhamer JH, Hoffman GS et al. Pneumocystis carinii penumonia: a major complication of immunosuppressive therapy in Wegener’s granulomatosis. Am. J. Respir. Crit. Care Med.151, 795–599 (1995).
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: an analysis of 158 patients. Ann. Intern. Med.116, 488–498 (1992).
   PubMed Web of Science ®Google Scholar
• Godeau B, Mainardi JL, Roudot-Thoraval F et al. Factors associated with Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. Ann. Rheum. Dis.54, 246–251 (1995).
   Google Scholar
• Mukhtyar C, Flossmann O, Hellmich B et al. Outcomes from studies of antineutrophils cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann. Rheum. Dis.67, 1004–1010 (2008).
   PubMed Web of Science ®Google Scholar
• Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin. Exp. Rheumatol.26(Suppl. 51), S94–S104 (2008).
   Google Scholar
• Hellmich B, Ehlers S, Csernok E et al. Update on the pathogenesis of Churg–Strauss syndrome. Clin. Exp. Rheumatol.21(6 Suppl. 32), S69–S77 (2003).
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Guilpain P, Guillevin L. Churg–Strauss syndrome. Curr. Opin. Rheumatol.19(1), 25–32 (2007).
   PubMed Web of Science ®Google Scholar
• Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinial trials in systemic vasculitis: focus in anti-neutrophil cytoplasm antibody-associated vasculitis. Ann. Rheum. Dis.66, 605–617 (2007).
   PubMed Web of Science ®Google Scholar